OMER Took an Omertà

A little bit of a creative license taken with that blog post title on a slow, June afternoon does not change the fact that Omeros (first daily chart, below) is the visible winner in biotech today. Note the tight base breakout. Holding $17 now would be a very bullish development for the Seattle-based biopharmaceutical company.

OMER is keeping its strength quiet and not "ratting out" its peers sluggishness today in the XBI, small and mid-cap biotech ETF.

But there are a few hidden gems we want to keep tabs on this summer. BLUE, on the second daily chart, is certainly one of them, what with its recent surge above $100. As long as that $90/$100 convert into support this summer BLUE is a strong candidate to regain some footing. 

We have a few other ideas in this arena, which I will flesh out in my recap for Members tonight, along with the market at-large.